Advancing the Science

Mayo Clinic Medical Science Blog

Share this:
May 3, 2016


By Elizabeth Zimmermann

Determining which drug works better for which patients

"Our findings definitely point toward important age-related risk that merits consideration when doctors are making treatment recommendations," says lead author Neena S. Abraham, M.D.

To the average TV viewer, it may seem like new drugs flood the marketplace daily.However, from the 1950s until just recently, warfarin was the only available anticoagulant drug approved by the Food and Drug Administration (FDA) to prevent blood clotting. One of the most common reasons people take an anticoagulant is to reduce stroke and heart attack risk related to atrial fibrillation, an irregular and often rapid heart rate that commonly causes poor blood flow. The condition affects 3 million Americans.Warfarin is so powerful and long-acting, though, that it may reduce beneficial clotting. Users must have regular blood tests to ensure they don't experience excessive bleeding, especially in the gastrointestinal (GI) tract, where it can be life-threatening.

Three new oral anticoagulants received FDA approval in just the past few years, and two of them — dabigatran (Pradaxa) and rivaroxaban (Xarelto) — do not require regular trips to the doctor's office for blood monitoring. That convenience factor has caused a huge upswing in prescriptions, even though the newer medications can be more expensive than warfarin.

Although cost and convenience are important considerations, researchers at the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery wondered if physicians had the medical evidence they needed to prescribe the best anticoagulant on an individual basis.

Read more about their research and learn what providers may want to discuss with their patients when deciding the best treatment for the individual.


Tags: anticoagulant, atrial fibrillation, Center for the Science of Health Care Delivery, dabigatran, Findings, Kern Center, medical research, Neena Abraham, rivaroxaban, warfarin



Posts: 1
Joined: May 30, 2016
Posted by @henrrymo, May 29, 2016

“Determining which drug works better for which patients” is very important in clinical trials. However, it is usually hard for making this decision. So FDA plays a very vital role in this aspect to regulating the drug discovery field.


Posts: 1
Joined: Aug 21, 2015
Posted by @caroline91, May 31, 2016

Old or new? That’s really a question. But I do think, new doesn’t mean good and old do not always mean bad. What’s best is what suits for the patients.

Liked by Dynamin


Posts: 1
Joined: Jul 19, 2016
Posted by @dynamin, Jul 19, 2016

Perfect caroline, it doesn’t make any sense. Old one was also made after doing research. It relates to patient and its body what suits best.


Posts: 1
Joined: Jun 06, 2016
Posted by @alfachem, Jun 6, 2016

The so-called determination could be specific, in terms of the condition of patients. I mean specific medication for specific groups. Discovery of new drugs is necessary in current days.


Posts: 2
Joined: Jun 30, 2016
Posted by @alanlo, Jun 30, 2016

Convenience and cost are among the top priority for drug design and development, especially for the drugs needed by common diseases conditions, and they are also the top factors for precise medicines, or few people can burden the cost.


Posts: 6
Joined: Jul 18, 2017
Posted by @archibald, Jul 18, 2017

If the crowd needs it now, Discovery of new drugs is necessary in current days

Please login or register to post a comment.
Contact Us · Privacy Policy